CLINICAL TRIALS

Breast Cancer Clinical Trials in Alabama

10+ recruiting Breast Cancer trials in Alabama, simplified into plain English.

Informational only. Not medical advice. Always consult a qualified healthcare professional.
Data sourced from ClinicalTrials.gov (NLM/NIH).

ACTIVE NOT RECRUITINGPhase 3

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

NCT02032823 · Anchorage
ACTIVE NOT RECRUITINGPhase 3

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including tr

NCT04873362 · Birmingham
RECRUITINGEARLY/Phase 1

Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)

This clinical study will investigate the utility of Fludeoxyglucose (18F) fluoromisonidazole (FMISO), in patients diagnosed with triple negative breast cancer (stage II-IV disease), to monitor and predict the effect of i

NCT04861077 · Birmingham
RECRUITINGPhase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph

NCT05564377 · Birmingham
ACTIVE NOT RECRUITINGPhase 3

PALbociclib CoLlaborative Adjuvant Study

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- ea

NCT02513394 · Mobile
RECRUITINGPhase 1

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with loca

NCT06562192 · Birmingham
RECRUITING

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast

NCT03053193 · Birmingham
ACTIVE NOT RECRUITINGPhase 2

Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer

RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping

NCT00616967 · Birmingham
RECRUITINGPhase 3

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combinatio

NCT06103864 · Daphne
ACTIVE NOT RECRUITINGPhase 2

PhII ICb With/Without Erbitux in MBC Pts

The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.

NCT00248287 · Birmingham

RECOMMENDED RESOURCES FOR BREAST CANCER

🛡️

GoHealth

Medicare Specialist

Compare Medicare Advantage and Supplement plans with a licensed advisor. Many patients with chronic conditions qualify for $0-premium plans with extra benefits.

Check Your Coverage →
🧬

Color Health

CLIA Certified

Hereditary cancer genetic testing from $99. Understand your inherited risk for breast, ovarian, colon, and other cancers — with genetic counseling included.

Get Tested →

Clinicals AI may earn a referral fee. At no cost to you.

COMMON QUESTIONS

Are there Breast Cancer clinical trials in Alabama?

Yes. Clinicals AI lists 10+ recruiting Breast Cancer trials in Alabama sourced from ClinicalTrials.gov. Browse them above or search across all states.

How do I qualify for a Breast Cancer trial in Alabama?

Eligibility varies by study. Most trials require a confirmed Breast Cancer diagnosis, fall within a specific age range, and may have restrictions based on prior treatments. Review each listing's criteria and submit a contact request for more details.

Are Breast Cancer clinical trials free to join?

Most trials cover the investigational treatment and all study-related visits. Some also offer compensation for travel and time. Always confirm the cost structure with the trial coordinator before enrolling.